CORRELATION OF CLINICAL PHARMACOKINETIC PARAMETERS OF CISPLATIN WITH EFFICACY AND TOXICITY

被引:30
作者
DESOIZE, B [1 ]
MARECHAL, F [1 ]
MILLART, H [1 ]
CATTAN, A [1 ]
机构
[1] HOP MAISON BLANCHE, REIMS, FRANCE
关键词
PHARMACOKINETICS; CIS-DIAMMINEDICHLOROPLATINUM; LUNG CANCER;
D O I
10.1016/0753-3322(91)90109-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Twenty-two pharmacokinetic studies were carried out in 11 patients receiving cisplatin (20 mg/m2 per d) associated with etoposide (50 mg/m2 per d), as 5-day continuous infusions, every 4 weeks. Blood was withdrawn at 8:30 am from day 1-5. Within 15 min after taking the blood, an aliquot of plasma was filtered for the ultrafilterable platinum (UP) assay. Total platinum (TP) and UP were assayed by flameless atomic absorption. The plasma concentrations and AUC0-120h of TP were correlated with those of UP (P < 0.05 to P < 0.001). TP concentrations increased significantly during the infusion and with each successive course, whereas the increase of plasma concentration of UP during and between courses was not statistically significant. The responders had significantly higher levels of TP (AUC, concentrations) in the first and second courses than the non-responders. No renal toxicity was observed, nevertheless, the AUC0-120h of TP and UP were positively correlated with the serum creatinine (P < 0.05). The digestive intolerance (grade 1-3) was significantly correlated with TP concentrations and AUC0-120h. There was no statistical difference in UP concentrations either between responders and non-responders in any course, nor between toxic and non-toxic courses. Since etoposide was concomitantly administered, we can formulate the conclusion as follows: no "objective" response was observed in the patients with low TP plasma concentrations and AUC0-120h.
引用
收藏
页码:203 / 207
页数:5
相关论文
共 25 条
[1]  
BANNISTER SJ, 1978, CLIN CHEM, V24, P877
[2]  
BELLIVEAU JF, 1986, CANCER TREAT REP, V70, P1215
[3]  
BONI C, 1989, CANCER, V63, P638, DOI 10.1002/1097-0142(19890215)63:4<638::AID-CNCR2820630406>3.0.CO
[4]  
2-8
[5]   CONTINUOUS INFUSION OF HIGH-DOSE CISPLATIN IN CHILDREN - PHARMACOKINETICS OF FREE AND TOTAL PLATINUM [J].
BUESCHARBIT, M ;
GENTET, JC ;
BERNARD, JL ;
BREANT, V ;
CANO, JP ;
RAYBAUD, C .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (11) :1649-1652
[6]   PILOT-STUDY OF A CONTINUOUS 5-DAY INTRAVENOUS-INFUSION OF ETOPOSIDE CONCOMITANT WITH CISPLATIN IN SELECTED PATIENTS WITH ADVANCED CANCER [J].
CREAGAN, ET ;
RICHARDSON, RL ;
KOVACH, JS .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) :1197-1201
[7]   CISPLATIN METABOLITES IN PLASMA, A STUDY OF THEIR PHARMACOKINETICS AND IMPORTANCE IN THE NEPHROTOXIC AND ANTITUMOUR ACTIVITY OF CISPLATIN [J].
DALEYYATES, PT ;
MCBRIEN, DCH .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (19) :3063-3070
[8]   SUPERIORITY OF PERFUSION OVER BOLUS ADMINISTRATION IN CANCER-CHEMOTHERAPY - PROPOSITION OF A COMPARTMENTAL MODEL [J].
DESOIZE, B ;
GARRETT, ER .
MEDICAL HYPOTHESES, 1989, 29 (01) :21-24
[9]   CLINICAL PHARMACOKINETICS OF ETOPOSIDE DURING 120 HOURS CONTINUOUS INFUSIONS IN SOLID TUMORS [J].
DESOIZE, B ;
MARECHAL, F ;
CATTAN, A .
BRITISH JOURNAL OF CANCER, 1990, 62 (05) :840-841
[10]  
DURAND RE, 1987, CANCER TREAT REP, V71, P673